## Supplementary information

## Synergistic Combinations of Multiple Chemotherapeutic Agents in a High Capacity Poly(2-oxazoline)s Polymeric Micelles

Yingchao Han ${ }^{\text {a,b,\#, Zhijian }} \mathrm{He}^{\mathrm{a}, \#}$, Anita Schulz ${ }^{\mathrm{c}}$, Rainer Jordan ${ }^{\mathrm{c}}$, Tatiana K. Bronich ${ }^{\mathrm{a}}$, Robert Luxenhofer ${ }^{\mathrm{c},{ }^{*}}$, Alexander V. Kabanov ${ }^{\text {a,d,* }}$
${ }^{a}$ Center for Drug Delivery and Nanomedicine and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-5830, United States; ${ }^{\text {b }}$ Biomedical Materials and Engineering Center, Wuhan University of Technology, Wuhan 430070, P.R. China; ${ }^{c}$ Professur für Makromolekulare Chemie, Department Chemie, Technische Universität Dresden, Zellescher Weg 19, 01069 Dresden, Germany; ${ }^{\text {d }}$ Laboratory of Chemical Design of Bionanomaterials, Faculty of Chemistry, M.V. Lomonosov Moscow State University, Moscow 119992, Russia


Fig. S1. Chemical structures of anti-cancer drugs.


Fig. S2. Attenuated total reflectance Fourier transform infrared (ATR FT-IR) spectra of (a) amphiphilic block copolymer alone, and POx block copolymer micelles loaded with (b) PTX, (c) 17-AAG, and (d) combination of PTX and 17-AAG. Incorporation of drugs into POx micelles was confirmed by ATR FT-IR spectra. For example, compared to the spectrum of POx polymer alone (a), additional vibrational bands at $709 \mathrm{~cm}^{-1}, 1070 \mathrm{~cm}^{-1}, 1239 \mathrm{~cm}^{-1}$ and $1719 \mathrm{~cm}^{-1}$ for PTX loaded POx micelles were observed (b). These bands represented characteristic group vibrations of PTX such as the out-of-plane ring bending of $\mathrm{Ph}-\mathrm{R}$ group, in-plane $\mathrm{C}-\mathrm{H}$ bending of $\mathrm{Ph}-\mathrm{R}$ group, $\mathrm{C}-\mathrm{O}-\mathrm{C}$ stretching of -COO- group, and $\mathrm{C}=\mathrm{O}$ stretching of PhCOO- group respectively. Accordingly, the spectrum of 17-AAG loaded micelles exhibited characteristic vibrational bands of 17-AAG. For example, the vibrational band at $1727 \mathrm{~cm}^{-1}$ was attributed to $\mathrm{C}=\mathrm{O}$ stretching of NH 2 COO - group; the vibrational band at $1688 \mathrm{~cm}^{-1}$ to $\mathrm{C}=\mathrm{O}$ stretching in quinine; and the vibrational band at $1099 \mathrm{~cm}^{-1}$ to $\mathrm{C}-\mathrm{O}$ stretching of (R) $)_{2} \mathrm{CH}-\mathrm{OH}$ group (c). For PTX/17-AAG co-loaded micelles, typical vibrational bands from both PTX and 17-AAG were observed including $709 \mathrm{~cm}^{-1}, 1105 \mathrm{~cm}^{-1}, 1241 \mathrm{~cm}^{-1}, 1692 \mathrm{~cm}^{-1}$, and $1723 \mathrm{~cm}^{-1}$ (d). 2.2 .5 . ATR FT-IR spectra of dried POx powders and freeze-dried drug loaded micellar formulations were obtained on a Nicolet 380 system (Thermo Scientific, Waltham, MA, USA) with a SilverGate ${ }^{\text {TM }}$ Evolution ATR accessory (Specac, Cranston, RI). The spectra were recorded at room temperature between $400 \mathrm{~cm}^{-1}$ and $4000 \mathrm{~cm}^{-1}$ at $4 \mathrm{~cm}^{-1}$ spectral resolution and compared to verify the incorporation of drugs into POx micelles.


Fig. S3. (a) Size distribution (as determined by DLS) of POx micelles loaded with single drugs: PTX $(\square)$, 17-AAG $(\bigcirc)$, DTX $(\triangle)$, ETO $(\nabla)$, and BTZ ( $\downarrow$ ); (b) Stability studies of POx micelles loaded with single drugs as in (a) by plotting average size (nm) and PDI over consecutive time points (days). (b) Measurement ended at 14 days. Lines between data points are for illustration purpose only.


Fig. S4. AFM topography scans of drug-loaded micelles of POx along with size distribution analysis of micelles (size (nm) vs. count) from an arbitrary area. (a) POx with PTX; (b) POx with 17-AAG; (c) POx with PTX and 17-AAG. Scan area is $2 \mu \mathrm{~m}^{2}$. Morphological studies on dried samples by AFM suggest that PTX/17-AAG co-loaded POx micelles retain spherical shape resembling those of single drug PTX or 17-AAG micelles.


Fig. S5. CLSM images of MCF-7 cells incubated with (a) free PTX, (b) POx block copolymer alone and (c) POx micelles co-loaded with PTX and 17-AAG for 4 h . Blue: Cell nuclei staining by Hoechst 33342; Green: BODIPY ${ }^{\circledR}$ FL PTX; Red: AF647 labeled POx. Scale bars are $20 \mu \mathrm{~m}$.


Fig. S6. The viability of the MCF7, MDA-MB-231, HepG2 and PC3 cells after their treatment for 24 h to different concentrations of amphiphilic POx block copolymer. Data are mean $\pm$ SEM $(n=6)$.


Fig. S7. The viability of the HepG2, PC3, and MDA-MB-231 cells after their treatment for 24 h with the micellar BTZ, 17-AAG and BTZ/17-AAG combination. Data are mean $\pm \operatorname{SEM}(\mathrm{n}=6)$.


Fig. S8. (a) Cytotoxicity of single drugs and two-drug combination, BTZ/17-AAG solublized in POx micelles in MCF7/ADR cells (left, mean $\pm$ SEM, $n=6$ ) and (b) the corresponding log CI vs. $\mathrm{F}_{\mathrm{a}}$ plot (right). (a) The total drug concentration is presented for two drug combination.

Table S1. Yields of drug loaded POx micelles.

| Drugs | Yield (\%) ${ }^{\text {a }}$ |
| :---: | :---: |
| PTX | $99.2 \pm 1.5$ |
| DTX | $99.1 \pm 1.0$ |
| 17-AAG | $96.1 \pm 1.5$ |
| ETO | $97.4 \pm 1.3$ |
| BTZ | $93.7 \pm 0.9$ |
| PTX <br> 17-AAG | $97.7 \pm 2.0$ |
| DTX <br> 17-AAG | $97.9 \pm 1.1$ |
| PTX <br> ETO | $95.2 \pm 2.7$ |
| ETO <br> 17-AAG | $94.8 \pm 1.4$ |
| PTX <br> BTZ | $93.2 \pm 3.9$ |
| BTZ <br> 17-AAG | $91.8 \pm 1.1$ |
| PTX <br> 17-AAG <br> ETO | $88.6 \pm 1.8$ |
| PTX <br> 17-AAG <br> BTZ | $88.1 \pm 1.2$ |
| DTX | $90.6 \pm 3.6^{\mathrm{b}}$ |
| PTX | $88.7 \pm 2.6^{\mathrm{c}}$ |

${ }^{\text {a }}$ The formulations presented in this table are same as those presented in Table 1. Unless stated otherwise the POx block copolymer $\left[\mathrm{P}\left(\mathrm{MeOx}_{40}-\mathrm{b}-\mathrm{BuOx}_{21}-\mathrm{b}-\mathrm{MeOx}_{34}\right)\right]$ was used and its concentration in the dispersion was $10 \mathrm{~g} / \mathrm{L}$. The yield of drug loaded micelles was determined as the ratio (initial POx weight + loaded drug weight) / (initial POx weight + feeding drug weight), ( $\mathrm{n}=3 \pm \mathrm{SD})^{\mathrm{b}} 50 \mathrm{~g} / \mathrm{L}$ POx and DTX was used in this experiment. ${ }^{\mathrm{c}} 50 \mathrm{~g} / \mathrm{L}$ POx and PTX was used along with a different batch of POx copolymer $\left[\mathrm{P}\left(\mathrm{MeOx}_{33}-\mathrm{b}-\mathrm{BuOx}_{26}-\mathrm{b}-\mathrm{MeOx}_{45}\right)\right]$.

Table S2. Characteristics of the drug release from POx micelles.

| Drugs in POx micelles | $\mathrm{t}_{1 / 2}(\mathrm{~h})$ | Drug released at $24 \mathrm{~h}(\%)$ | Drug released ratio at $24 \mathrm{~h}^{\mathrm{a}}$ |
| :---: | :---: | :---: | :---: |
| PTX | 18 | 67 | n.a. |
| 17-AAG | 6 | 96 | n.a. |
| BTZ | 4 | 99 | n.a. |
| ETO | 3 | 99 | n.a. |
| PTX | 15 | 68 | $1.0: 1.4$ |
| 17-AAG | 7 | 95 | $1.0: 1.6$ |
| PTX | 20 | 60 | $1.0: 1.0$ |
| BTZ | 2 | 99 | $1.0: 1.5$ |
| 17-AAG | 6 | 96 | $1.0: 1.0$ |
| BTZ | 3 | 99 |  |
| PTX | 18 | 63 | $1.0: 1.6: 1.6$ |
| ETO | 5 | 98 |  |
| 17-AAG | 7 | 96 |  |
| ETO | 5 | 98 | $1: 1.7: 1.8$ |
| PTX | 18 | 61 |  |
| 17-AAG | 8 | 95 |  |
| BTZ | 3 | 97 | 55 |
| PTX | 21 | 92 | 98 |
| 17-AAG | 8 | 9 | 98 |
| ETO |  |  |  |

[^0]Table S3 Comparison of our results with others for drug formulation in LC and DL values

| Drugs | Our results ${ }^{\text {a }}$ |  |  | G.S. Kwon group's results |  |  |
| :---: | :---: | :---: | :---: | :---: | :---: | :---: |
|  | Solution drug concentration $(\mathrm{g} / \mathrm{L})$ | $L C$ (\%) | DL (\%) | Solution drug concentration $(\mathrm{g} / \mathrm{L})$ | $L C^{\text {d }}$ (\%) | $D L^{\mathrm{e}}$ (\%) |
| PTX | 3.88 | 27.9 | 38.8 | 3.54 | 9.3 | 10.3 |
| DTX | 3.87 | 27.9 | 38.7 | 4.27 | 10.3 | 11.5 |
| 17-AAG | 3.45 | 25.6 | 34.5 | 3.90 | 10.2 | 11.3 |
| ETO | 3.62 | 26.6 | 36.4 | 3.31 | 8.7 | 9.6 |
| BTZ | 3.12 | 23.8 | 31.2 | 1 | 1 | 1 |
| PTX | 3.66 | 43.1 | 75.9 | 3.92 | 20.6 | 25.9 |
| 17-AAG | 3.93 |  |  | 3.88 |  |  |
| DTX | 3.92 | 43.3 | 76.3 | 4.62 | 20.5 | 25.8 |
| 17-AAG | 3.70 |  |  | 4.01 |  |  |
| PTX | 3.59 | 41.6 | 71.4 | 1 | 1 | 1 |
| ETO | 3.54 |  |  |  |  |  |
| ETO | 3.69 | 41.1 | 70.7 | 3.49 | 20.0 | 25.0 |
| 17-AAG | 3.38 |  |  | 4.21 |  |  |
| PTX | 3.27 | 40.3 | 67.8 | 1 | 1 | 1 |
| BTZ | 3.52 |  |  |  |  |  |
| BTZ | 3.27 | 39.5 | 65.2 | 1 | 1 | 1 |
| 17-AAG | 3.25 |  |  |  |  |  |
| PTX | 3.01 | 48.7 | 94.8 | 3.50 | 26.2 | 35.6 |
| 17-AAG | 3.19 |  |  | 3.61 |  |  |
| ETO | 3.27 |  |  | 3.17 |  |  |
| PTX | 3.18 | 48.4 | 93.8 | 1 | 1 | 1 |
| 17-AAG | 3.03 |  |  |  |  |  |
| BTZ | 3.17 |  |  |  |  |  |
| DTX ${ }^{\text {b }}$ | 40.6 | 44.8 | 81.2 | 1 | 1 | 1 |
| PTX ${ }^{\text {c }}$ | 38.71 | 43.6 | 77.4 | 1 | 1 | 1 |

${ }^{a}$ Unless stated otherwise the POx copolymer $\mathrm{P}\left(\mathrm{MeOx}_{40}-\mathrm{b}-\mathrm{BuOx}_{21}-\mathrm{b}-\mathrm{MeOx}_{34}\right)$ was used and its concentration in the dispersion was $10 \mathrm{~g} / \mathrm{L} .{ }^{\mathrm{b}} 50 \mathrm{~g} / \mathrm{L}$ POx and DTX was used in this experiment. ${ }^{\mathrm{c}} 50 \mathrm{~g} / \mathrm{L}$ POx and PTX was used along with a different batch of POx copolymer $\mathrm{P}\left(\mathrm{MeOx}_{33}-\mathrm{b}-\mathrm{BuOx}_{26}-\mathrm{b}-\mathrm{MeOx}_{45}\right)$. ${ }^{\mathrm{d}}$ Recalculated value according to LC equation. ${ }^{\mathrm{e}}$ Original reported data. (H.C. Shin, A.W.G. Alani, D.A. Rao, N.C. Rockich, G.S. Kwon, Multi-drug loaded polymeric micelles for simultaneous delivery of poorly soluble anticancer drugs, J. Control. Release 140 (2009) 294-300)

$$
\begin{align*}
& L C=\frac{m_{\text {drug }}}{m_{\text {drug }}+m_{\text {excipient }}} \cdot 100 \%  \tag{1}\\
& D L=\frac{m_{\text {drug }}}{m_{\text {excipient }}} \cdot 100 \% \tag{2}
\end{align*}
$$


[^0]:    ${ }^{\text {a }}$ Determined as the fraction of the drug released relative to the slowest released drug in the drug combination.

